Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials-Reference-Cited by-同舟云学术

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

Published:2019-12-11 Issue:4 Volume:22 Page:699-704
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Abd El Aziz Mirna¹,Cahyadi Oscar¹,Meier Juris J.¹^ORCID,Schmidt Wolfgang E.¹,Nauck Michael A.¹^ORCID

Affiliation:

1. Diabetes Division, Department of Medicine I, St. Josef‐Hospital (Ruhr‐University Bochum), Gudrunstraße 56, D‐44791 Bochum Germany

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13924

Reference30 articles.

1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

2. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors

3. Exenatide and rare adverse events;Ahmad SR;N Engl J Med,2008

4. Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

5. A Critical Analysis of the Clinical Use of Incretin-Based Therapies

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13

2. Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report;Frontiers in Endocrinology;2024-09-06

3. The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis;Diabetes Research and Clinical Practice;2024-09

4. Advances in small-molecule insulin secretagogues for diabetes treatment;Biomedicine & Pharmacotherapy;2024-09

5. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review;eClinicalMedicine;2024-09